TIR-domain-containing adapter-inducing interferon-β (TRIF) regulates Th17-mediated intestinal immunopathology in colitis

Mucosal Immunology

Volumn 8, Issue 2, 2015, Pages 296-306

  Kanagavelu, S ^a,b   Flores, C ^b   Termini, J M ^a   Riveron, R ^a   Romero, L ^a   Chung, K ^a   Ruiz, J ^a   Hyun, J ^a   Yuan, X ^a   Dagvadorj, J ^b   Fukata, M ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERLEUKIN 27; PROTEIN P28; STAT1 PROTEIN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; GAMMA INTERFERON; TICAM-1 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLONOSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL MUCOSA; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; IMMUNOREGULATION; INNATE IMMUNITY; LAMINA PROPRIA; MACROPHAGE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PLASTICITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TH17 CELL; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; KNOCKOUT MOUSE; METABOLISM; MICROBIOLOGY; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; CELL DIFFERENTIATION; COLITIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; INTERFERON-GAMMA; INTERLEUKIN-27; INTESTINAL MUCOSA; MACROPHAGES; MICE; MICE, KNOCKOUT; SEVERITY OF ILLNESS INDEX; STAT1 TRANSCRIPTION FACTOR; TH17 CELLS;

EID: 84922749649     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2014.67     Document Type: Article

References (41)

1. Round, J.L. & Mazmanian, S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9, 313-323 (2009).
2. McGovern, D. & Powrie, F. The IL23 axis plays a key role in the pathogenesis of IBD. Gut 56, 1333-1336 (2007).
3. Becker, C., et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest. 112, 693-706 (2003).
4. Mannon, P.J., et al. Anti-interleukin-12 antibody for active Crohns disease. N. Engl. J. Med. 351, 2069-2079 (2004).
5. Sandborn, W.J., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-tosevere Crohns disease. Gastroenterology 135, 1130-1141 (2008).
6. Hueber, W., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohns disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693-1700 (2012).
7. Symons, A., Budelsky, A.L. & Towne, J.E. Are Th17 cells in the gut pathogenic or protective?. Mucosal Immunol. 5, 4-6 (2012).
8. OConnor, W. Jr., Zenewicz, L.A. & Flavell, R.A. The dual nature of T(H)17 cells: shifting the focus to function. Nat. Immunol. 11, 471-476 (2010).
9. Mucida, D. T-helping colitis. Gastroenterology 141, 801-805 (2011).
10. McGeachy, M.J., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 8, 1390-1397 (2007).
11. Louten, J., Boniface, K. & deWaal Malefyt, R.Development and function of TH17 cells in health and disease. J. Allergy Clin. Immunol. 123, 1004-1011 (2009).
12. Bi, Y., Liu, G. & Yang, R. Reciprocal modulation between TH17 and other helper T cell lineages. J. Cell. Physiol. 226, 8-13 (2011).
13. Hovhannisyan, Z., Treatman, J., Littman, D.R. & Mayer, L.Characterization of interleukin-17-producing regulatory Tcells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140, 957-965 (2011).
14. Sarra, M., Pallone, F., Macdonald, T.T. & Monteleone, G. IL-23/IL-17 axis in IBD. Inflamm. Bowel Dis. 16, 1808-1813 (2010).
15. Atarashi, K., et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 455, 808-812 (2008).
16. Ivanov, I.I., et al. Specific microbiota direct the differentiation of IL-17- producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337-349 (2008).
17. Shaw, M.H., Kamada, N., Kim, Y.G. & Nunez, G. Microbiota-induced IL-1beta, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J. Exp. Med. 209, 251-258 (2012).
18. Guo, B., Chang, E.Y. & Cheng, G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118, 1680-1690 (2008).
19. De Luca, A., et al. Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. J. Immunol. 179, 5999-6008 (2007).
20. Ahern, P.P., et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33, 279-288 (2010).
21. Diveu, C., et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J. Immunol. 182, 5748-5756 (2009).
22. Ramgolam, V.S., Sha, Y., Jin, J., Zhang, X. & Markovic-Plese, S. IFN-beta inhibits human Th17 cell differentiation. J. Immunol. 183, 5418-5427 (2009).
23. Kullberg, M.C., et al. IL-23 plays a key role in Helicobacter hepaticusinduced T cell-dependent colitis. J. Exp. Med. 203, 2485-2494 (2006).
24. Elson, C.O., et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132, 2359-2370 (2007).
25. OConnor, W. Jr., et al. A protective function for interleukin 17A in T cellmediated intestinal inflammation. Nat. Immunol. 10, 603-609 (2009).
26. Leppkes, M., et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136, 257-267 (2009).
27. Lee, Y.K., et al. Late developmental plasticity in the T helper 17 lineage. Immunity 30, 92-107 (2009).
28. Zhang, Z., Zheng, M., Bindas, J., Schwarzenberger, P. & Kolls, J.K. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm. Bowel Dis. 12, 382-388 (2006).
29. Jin, Y., Lin, Y., Lin, L. & Zheng, C. IL-17/IFN-gamma interactions regulate intestinal inflammation in TNBS-induced acute colitis. J. Interferon Cytokine Res. 32, 548-556 (2012).
30. Geremia, A., et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208, 1127-1133 (2011).
31. Mikami, Y., et al. Competition between colitogenic Th1 and Th17 cells contributes to the amelioration of colitis. Eur. J. Immunol. 40, 2409-2422 (2010).
32. Basu, R., Hatton, R.D. & Weaver, C.T. The Th17 family: flexibility follows function. Immunol. Rev. 252, 89-103 (2013).
33. Hanson, M.L., et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 146, 210-21, e13 (2014).
34. Visperas, A., Do, J.S., Bulek, K., Li, X. & Min, B. IL-27, targeting antigenpresenting cells, promotes Th17 differentiation and colitis in mice. Mucosal Immunol. 7, 625-633 (2013).
35. Mascanfroni, I.D., et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat. Immunol. 14, 1054-1063 (2013).
36. Villarino, A.V., Gallo, E. & Abbas, A.K. STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms. J. Immunol. 185, 6461-6471 (2010).
37. Imielinski, M., et al. Common variants at five new loci associated with earlyonset inflammatory bowel disease. Nat. Genet. 41, 1335-1340 (2009).
38. Kjellev, S., Lundsgaard, D., Poulsen, S.S. &Markholst, H. Reconstitution of Scid mice with CD4+CD25- T cells leads to rapid colitis: an improved model for pharmacologic testing. Int. Immunopharmacol. 6, 1341-1354 (2006).
39. Cong, Y., et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J. Exp. Med. 187, 855-864 (1998).
40. Sotolongo, J., et al. Host innate recognition of an intestinal bacterial pathogen induces TRIF-dependent protective immunity. J. Exp. Med. 208, 2705-2716 (2011).
41. Fukata, M., et al. The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J. Immunol. 180, 1886-1894 (2008).